Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 in small cell lung cancer and neuroendocrine carcinoma
NCT05978284Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Oct 2023; status: recruiting.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05978284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978284.